The effect of time since measles vaccination and age at first dose on measles vaccine effectiveness - A systematic review.
Eliminated
Endemic
Immunisation
Measles
Vaccine effectiveness
Waning immunity
Journal
Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899
Informations de publication
Date de publication:
16 01 2020
16 01 2020
Historique:
received:
03
06
2019
revised:
16
09
2019
accepted:
27
10
2019
pubmed:
17
11
2019
medline:
13
2
2021
entrez:
17
11
2019
Statut:
ppublish
Résumé
In settings where measles has been eliminated, vaccine-derived immunity may in theory wane more rapidly due to a lack of immune boosting by circulating measles virus. We aimed to assess whether measles vaccine effectiveness (VE) waned over time, and if so, whether differentially in measles-eliminated and measles-endemic settings. We performed a systematic literature review of studies that reported VE and time since vaccination with measles-containing vaccine (MCV). We extracted information on case definition (clinical symptoms and/or laboratory diagnosis), method of vaccination status ascertainment (medical record or vaccine registry), as well as any biases which may have arisen from cold chain issues and a lack of an age at first dose of MCV. We then used linear regression to evaluate VE as a function of age at first dose of MCV and time since MCV. After screening 14,782 citations, we identified three full-text articles from measles-eliminated settings and 33 articles from measles-endemic settings. In elimination settings, two-dose VE estimates increased as age at first dose of MCV increased and decreased as time since MCV increased; however, the small number of studies available limited interpretation. In measles-endemic settings, one-dose VE increased by 1.5% (95% CI 0.5, 2.5) for every month increase in age at first dose of MCV. We found no evidence of waning VE in endemic settings. The paucity of data from measles-eliminated settings indicates that additional studies and approaches (such as studies using proxies including laboratory correlates of protection) are needed to answer the question of whether VE in measles-eliminated settings wanes. Age at first dose of MCV was the most important factor in determining VE. More VE studies need to be conducted in elimination settings, and standards should be developed for information collected and reported in such studies.
Sections du résumé
BACKGROUND
In settings where measles has been eliminated, vaccine-derived immunity may in theory wane more rapidly due to a lack of immune boosting by circulating measles virus. We aimed to assess whether measles vaccine effectiveness (VE) waned over time, and if so, whether differentially in measles-eliminated and measles-endemic settings.
METHODS
We performed a systematic literature review of studies that reported VE and time since vaccination with measles-containing vaccine (MCV). We extracted information on case definition (clinical symptoms and/or laboratory diagnosis), method of vaccination status ascertainment (medical record or vaccine registry), as well as any biases which may have arisen from cold chain issues and a lack of an age at first dose of MCV. We then used linear regression to evaluate VE as a function of age at first dose of MCV and time since MCV.
RESULTS
After screening 14,782 citations, we identified three full-text articles from measles-eliminated settings and 33 articles from measles-endemic settings. In elimination settings, two-dose VE estimates increased as age at first dose of MCV increased and decreased as time since MCV increased; however, the small number of studies available limited interpretation. In measles-endemic settings, one-dose VE increased by 1.5% (95% CI 0.5, 2.5) for every month increase in age at first dose of MCV. We found no evidence of waning VE in endemic settings.
CONCLUSIONS
The paucity of data from measles-eliminated settings indicates that additional studies and approaches (such as studies using proxies including laboratory correlates of protection) are needed to answer the question of whether VE in measles-eliminated settings wanes. Age at first dose of MCV was the most important factor in determining VE. More VE studies need to be conducted in elimination settings, and standards should be developed for information collected and reported in such studies.
Identifiants
pubmed: 31732326
pii: S0264-410X(19)31479-3
doi: 10.1016/j.vaccine.2019.10.090
pmc: PMC6970218
pii:
doi:
Substances chimiques
Measles Vaccine
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
460-469Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Informations de copyright
Crown Copyright © 2019. Published by Elsevier Ltd. All rights reserved.
Références
J Infect Dis. 1992 Jul;166(1):205-8
pubmed: 1607699
J Paediatr Child Health. 1993 Dec;29(6):455-8
pubmed: 8286163
Western Pac Surveill Response J. 2015 Jul 09;6(3):43-50
pubmed: 26668766
N Z Med J. 1992 Jul 22;105(938):280-2
pubmed: 1495660
J Korean Med Sci. 2017 Nov;32(11):1876-1878
pubmed: 28960044
J Infect Dis. 2012 Nov 15;206(10):1542-8
pubmed: 22966129
Br Med J (Clin Res Ed). 1985 Dec 14;291(6510):1685
pubmed: 3935243
Commun Dis Intell Q Rep. 2009 Mar;33(1):21-6
pubmed: 19618764
J Infect Dis. 2004 May 1;189 Suppl 1:S116-22
pubmed: 15106100
Indian J Public Health. 2013 Oct-Dec;57(4):272-5
pubmed: 24351391
MMWR Morb Mortal Wkly Rep. 2007 Apr 6;56(13):304-7
pubmed: 17410083
J Infect Dis. 2014 Sep 1;210(5):693-700
pubmed: 24688075
Vaccine. 2018 Feb 28;36(10):1248-1255
pubmed: 29398276
Euro Surveill. 2019 Apr;24(17):
pubmed: 31039834
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
Med J Aust. 1995 May 1;162(9):471-5
pubmed: 7746203
J Infect Dis. 2016 Dec 15;214(12):1980-1986
pubmed: 27923955
BMC Int Health Hum Rights. 2016 Apr 13;16:13
pubmed: 27074957
J Trop Pediatr. 2009 Aug;55(4):253-6
pubmed: 18799515
BMC Infect Dis. 2018 Jan 8;18(1):21
pubmed: 29310585
Pediatr Infect Dis J. 1996 Dec;15(12):1082-6
pubmed: 8970216
Bull World Health Organ. 1982;60(5):767-75
pubmed: 6983927
Vaccine. 2009 Dec 9;27(52):7219-21
pubmed: 19833246
Pediatr Infect Dis J. 1994 Jan;13(1):38-45
pubmed: 8170731
Vaccine. 2017 Jul 24;35(33):4126-4132
pubmed: 28669617
Southeast Asian J Trop Med Public Health. 2006 Jan;37(1):96-101
pubmed: 16771219
Lancet. 1999 Jan 9;353(9147):98-102
pubmed: 10023894
Epidemiol Infect. 1994 Oct;113(2):367-75
pubmed: 7925673
Vaccine. 2011 Oct 19;29(45):8024-31
pubmed: 21893145
J Infect Dis. 2011 Jul;204 Suppl 1:S133-48
pubmed: 21666154
J Commun Dis. 1988 Mar;20(1):38-43
pubmed: 3230287
Vaccine. 2006 May 8;24(19):4111-5
pubmed: 16554111
MMWR Morb Mortal Wkly Rep. 2017 Oct 27;66(42):1148-1153
pubmed: 29073125
Vaccine. 2001 Mar 21;19(17-19):2258-61
pubmed: 11257344
Vaccine. 2003 Nov 7;21(31):4597-603
pubmed: 14575773
Pediatr Infect Dis J. 1995 May;14(5):346-9
pubmed: 7638007
BMJ. 2016 Oct 12;355:i4919
pubmed: 27733354
Vaccine. 2008 Dec 9;26(52):6980-5
pubmed: 18805455
J Infect Dis. 2019 Nov 6;220(12):1870-1872
pubmed: 30615164
Epidemiol Infect. 2010 Mar;138(3):415-25
pubmed: 19678973
BMJ. 2010 May 18;340:c1626
pubmed: 20483946
Cent Afr J Med. 1996 Jul;42(7):195-7
pubmed: 8936783
Rev Infect Dis. 1988 Mar-Apr;10(2):457-62
pubmed: 3273479
MMWR Morb Mortal Wkly Rep. 2015 Oct 02;64(38):1088-92
pubmed: 26421903
J Infect Dis. 2016 Jun 15;213(12):2005-13
pubmed: 26908733
Vaccine. 2003 Jan 17;21(5-6):473-8
pubmed: 12531646
Am J Epidemiol. 2001 Dec 1;154(11):1064-71
pubmed: 11724724
Clin Infect Dis. 2012 Aug;55(3):394-402
pubmed: 22543023
Cent Afr J Med. 1997 Sep;43(9):254-6
pubmed: 9509644
Pediatr Infect Dis J. 1998 Nov;17(11):1034-9
pubmed: 9849988
Lancet. 1983 Apr 30;1(8331):972-5
pubmed: 6132278
Indian Pediatr. 2002 Jun;39(6):556-60
pubmed: 12084949
Cent Afr J Med. 1995 Aug;41(8):241-5
pubmed: 7585910
BMJ. 2019 Feb 14;364:l739
pubmed: 30765388
Am J Epidemiol. 1999 Dec 1;150(11):1250-7
pubmed: 10588086
Epidemiol Infect. 1994 Apr;112(2):409-12
pubmed: 8150015